Sudarshan Pharma Industries Ltd plans to raise up to ₹1,500 crore via various methods, including QIP or private placement, to fuel growth. Concurrently, SPIL is expanding globally, establishing wholly-owned subsidiaries in Canada and the United States. These new ventures will manufacture and trade chemical, pharmaceutical and FMCG products, enabling SPIL's direct international market presence.